Intersect ENT (XENT) Misses Q4 EPS by 22c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Intersect ENT Reports Fourth Quarter and Full Year 2020 Financial Results
March 9, 2021 7:00 AM ESTMENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (ENT) medical technology leader dedicated to transforming patient care, today reported financial results for the fourth quarter and full year ended December 31, 2020.
Fourth Quarter 2020 Overview
Revenue totaled $28.2 million in the fourth quarter of 2020, compared to $31.8 million in the fourth quarter of 2019. SINUVA recorded a record revenue quarter of $2.6 million. The Fiagon product portfolio generated revenue of $0.9 million and included the first sales ever of the recently FDA-cleared VENSURE sinus... More